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        The IL-17 family of cytokines is composed of 
six members (IL-17A  –  F) that share little homol-
ogy to other cytokine families. The fi  rst described 
member, IL-17A (CTLA-8; referred to here-
after as IL-17), has been described as a pro-
infl  ammatory cytokine acting on epithelial and 
endothelial cells (  1  ). Increased production of 
IL-17 has been described in various human auto-
immune and allergic diseases, such as rheumatoid 
arthritis (  2  ), multiple sclerosis (  3  ), and asthma (  4  ). 
Animal models have mostly confi  rmed the cru-
cial pathological role of IL-17 in these diseases 
(  5  ). IL-17 is also indispensable for eradicating 
extracellular microorganisms, partly because of 
its ability to recruit neutrophils to the infected 
organs/tissues (  6, 7  ). 
  Intense focus has been put on defi  ning the 
cell types responsible for IL-17 production over 
the past few years. Initial animal studies looking 
at the role of IL-12 or -23 in experimental auto-
immune encephalomyelitis models identifi  ed 
the IL-23/-17 axis as a requirement for disease 
establishment (  8, 9  ). The major cell type respon-
sible for IL-17 production in this model was 
found to be CD4  +   Th cells. Th cell subsets have 
been classically divided into Th1 or Th2 based 
on their cytokine production profi  le, as well as 
expression of transcription factors (  5, 10, 11  ). 
Th1 cells are crucial for resistance to intracellu-
lar pathogens, secrete IFN-    , and require the 
transcription factor T-bet. Th2 cells are charac-
terized by the expression of GATA-3 and c-Maf, 
secrete IL-4, -5, and -13, and play a role in par-
asite clearance and allergic diseases. Initially, it 
was hypothesized that IL-17  –  producing Th cells 
might be derived from a progenitor that also 
gives rise to Th1 cells (  12  ). However, recent 
findings have defined the IL-17  –  producing 
cells as a new Th cell lineage, renamed Th17, 
which are characterized by their ability to secrete 
IL-17F and -22, in addition to IL-17 (  13  –  16  ). 
Diff  erentiation of Th17 cells requires TGF    1 and 
IL-6 both in vivo and in vitro. Although IL-23 
is required for the maintenance of Th17 cells 
in vivo, it cannot drive de novo diff  erentiation of 
naive Th cells (  13, 14, 16  ). Recently, the nuclear 
orphan receptor ROR    t has been found to be 
indispensable for the diff  erentiation of Th17 cells 
(  17  ). However, it is still unclear whether ROR    t 
directly controls IL-17 expression and what other 
transcription factors may be involved in regulat-
ing the diff  erentiation of this subset of Th cells. 
The diff  erentiation of Th17 cells is also subject to 
negative regulation by non-Th17 cytokines, such 
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as IL-4, IFN-    , IL-27, and IL-2 (  15, 18  –  20  ). It is believed that 
these cytokines inhibit the diff  erentiation of Th17 cells by 
suppressing the expression of ROR    t. 
  Ets-1, which is the prototype member of the Ets family of 
transcription factors, recognizes the conserved GGAA/T 
motif and binds DNA through the conserved Ets domain. 
Ets-1 has been shown to play a role in hematopoietic de-
velopment, angiogenesis, and tumor progression (  21  ). We 
have also previously demonstrated that defi  ciency in Ets-1 
has a profound impact on Th1 immune responses ( 22  ). Ets-1 – 
defi   cient (Ets-1 KO) Th1 cells produced abnormally low 
levels of IFN-    , IL-2, and TNF-    , but, unexpectedly, ex-
pressed a very high level of IL-10. However, the role of Ets-1 
in regulating the diff  erentiation and function of Th17 cells 
remains unknown. 
  We report that Ets-1 is a negative regulator of Th17 dif-
ferentiation. Ets-1 KO Th cells produced an increased level 
of IL-17 after diff  erentiation in the presence of TGF    1 and 
IL-6. Ets-1  –  defi  cient cells produced less IL-2 than WT cells. 
At the same time, they were resistant to IL-2 because of a 
defect downstream of STAT5 phosphorylation. However, the 
increased resistance to IL-2 did not lead to increased levels of 
ROR    t in diff  erentiating Ets-1 KO Th17 cells. Finally, Ets-1 
KO mice spontaneously expressed an abnormally high level 
of IL-17 in their lungs and exhibit mucus overproduction by 
their airway epithelial cells. This overproduction of mucus 
can be attenuated by an antibody against IL-17. 
    RESULTS   
  Expression and phosphorylation of Ets-1 in Th17 cells 
  Ets-1 is expressed in two forms (p55 and p42) in Th cells 
because of alternative splicing, and it can undergo phosphoryl-
ation in response to stimulation through T cell receptors 
(  23  –  25  ). The known phosphorylation sites of Ets-1 are Ser  251  , 
Ser  257  , Ser  282  , and Ser  285   (collectively termed 4S) and Thr  38  . 
The p42 isoform of Ets-1 lacks exon 7, and therefore does 
not contain the 4S phosphorylation site. Previous in vitro 
studies have indicated that these phosphorylation events sub-
stantially infl  uence the DNA-binding and -activating prop-
erties of Ets-1 (  25  –  29  ). To examine the role of Ets-1 in 
regulating the diff  erentiation of Th17 cells, we fi  rst set out to 
determine whether Ets-1 is expressed in Th17 and, if it is, 
whether Ets-1 can also undergo phosphorylation in activated 
Th17 cells. Th0, Th1, Th2, and Th17 cells were generated 
in vitro and restimulated with PMA/ionomycin for 4 h. The 
cytokine profi  le of each Th subset was confi  rmed by intracellular 
  Figure 1.     Ets-1 KO Th cells produce increased levels of IL-17. Total 
Th cells derived from WT or Ets-1 KO mice were cultured as described 
in the Materials and methods. (A) After 5 d in culture under Th0, Th1, 
Th2, or Th17 conditions, cells were restimulated with PMA/ionomycin 
for 10 min and lysed. Whole-cell extract was analyzed by Western 
blotting using antibodies against Ets-1 or phospho-T38 Ets-1. An anti-
body against Hsp90 was used as loading control. (B) Total Th cells 
from WT and Ets-1 KO mice were cultured under Th17 conditions for 
5 d and restimulated with PMA/ionomycin. Cytokine production was 
assessed by ICS. The numbers represent the percentages of cells 
stained positive for the indicated cytokines. (C) Total Ets-1 KO and WT 
Th cells were differentiated for 5 d in the presence of WT irradiated 
splenocytes and indicated cytokines, and the production of IL-17 in 
response to PMA/ionomycin stimulation was analyzed by ICS. The per-
centages of IL-17  –  positive cells from five independent experiments 
are shown. (D) Some of the differentiated Th cells (at 1 million cells/ml) 
generated in C were restimulated with 0.1     g/ml of plate-bound 
anti-CD3 for 24 h, and the level of IL-17 protein in the supernatant 
was measured by ELISA. (E) A fraction of the PMA/ionomycin-restimu-
lated cells from C were analyzed for IL-17 expression by real-time PCR 
analysis. (F) Naive WT and Ets-1 KO Th cells were differentiated under 
Th17 conditions, and the production of IL-17 by the differentiated 
cells was analyzed by ICS after 5 d. Cumulative results of six indepen-
dent experiments are shown. Data are presented as the mean   ±   the SD. 
*,  P   <   0.05.   
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  Increased IL-17 expression by Ets-1 KO Th17 cells 
is reversible and is caused by enhanced Th17 differentiation 
  Defi  ciency of Ets-1 also signifi  cantly alters the development 
of thymocytes (  30  –  32  ). To eliminate the possibility that in-
creased IL-17 production by Ets-1 KO Th17 cells is caused 
by aberrant lymphocyte development, we retrovirally trans-
duced diff  erentiating WT and Ets-1 KO Th17 cells with 
either a retrovirus expressing GFP alone (GFP-rv) or the 
full-length p55 Ets-1 isoform (Ets-1-rv). The expression of 
IL-17 by the transduced (GFP-positive) Th17 cells was ana-
lyzed by ICS. Expression of retroviral Ets-1 in WT Th17 
cells had only a minimal eff  ect on the number of IL-17  –  pro-
ducing cells compared with GFP-rv. The already high level of 
cytokine staining (ICS; Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20070994/DC1). The level and 
phosphorylation of Ets-1 proteins was then examined by 
Western analysis. As shown in   Fig. 1 A  , all Th subsets ex-
pressed comparable levels of both the full-length p55 and the 
alternatively spliced p42 Ets-1 isoforms.   In addition, phos-
phorylation of Thr  38   (as detected by anti-phosphoT38) and 
4S (as measured by a shift in the molecular weight of p55) 
was observed in all Th subsets. As expected, expression of 
Ets-1 was not detected in any of the Ets-1 KO Th subsets. 
  Increased IL-17 production by Ets-1 KO Th cells 
  To determine whether Ets-1 plays a role in regulating pro-
duction of cytokines by Th17 cells, we used intracellular 
  cytokine staining to compare the cytokine profi  les between 
WT and Ets-1 KO Th17 cells. Surprisingly, we found that 
Ets-1 KO Th17 cells produced an abnormally high level of 
IL-17 compared with WT cells. When diff  erentiated un-
der Th17 conditions,     6  –  10% of the diff  erentiated WT 
cells stained positive for IL-17, whereas   >  35% of Ets-1 KO 
Th17 cells produced IL-17 (  Fig. 1, B and C  ). We also ob-
served a substantial reduction in the level of IL-2 in Ets-1 
KO Th17 cells, a result that is consistent with our previous 
fi  ndings in Ets-1 KO Th1 cells (  22  ). However, the levels 
of IL-10 and IFN-     were relatively low, but comparable 
between WT and Ets-1 KO Th17 cells, suggesting that the 
role of Ets-1 in regulating the expression of these two cyto-
kines is Th subset dependent. Although defi  ciency of Ets-1 
leads to overproduction of IL-17, Ets-1 KO Th cells are not 
  “  preprogrammed  ”   to become IL-17  –  producing cells. When 
diff  erentiated in the absence of polarizing cytokines (Th0 
conditions), very little IL-17 was expressed by either WT 
or Ets-1 KO Th cells (  Fig. 1 C  ). Interestingly, polarization 
with IL-6 alone, but not TGF    1, already led to a signifi  cant 
increase in IL-17 production by Ets-1 KO cells, which was 
probably caused by the presence of a low level of TGF    1 in 
fetal calf serum (  Fig. 1 C  ). The increase in IL-17 staining of 
Ets-1 KO Th17 cells correlated very well with elevated levels 
of IL-17 protein in the supernatant of anti-CD3  –  stimulated 
Ets-1 KO Th17 cells, and with a marked increase in the level 
of IL-17 transcripts (  Fig. 1, D and E  ). Thus, defi  ciency of 
Ets-1 leads to increased IL-17 expression by Th17 cells, 
and this eff  ect of Ets-1 defi  ciency is mediated at the tran-
scriptional level. 
  Ets-1 KO mice have previously been reported to contain 
an increased number of memory T cells (  30  ). It is possible 
that Ets-1 KO APC preferentially drive Th cells into the 
Th17 pathway. Thus, the enhanced IL-17 production may 
simply refl  ect the presence of more memory Th17 cells in 
the starting bulk Ets-1 KO Th population. We found that 
WT and Ets-1 KO APCs were equally competent in sup-
porting the in vitro diff  erentiation of WT Th17 cells (unpub-
lished data). In addition, when naive CD4  +   CD62L  hi   CD25    −    Th 
cells were sorted and cultured under Th17 conditions, the 
diff  erentiated Ets-1 KO Th17 cells still exhibited overproduc-
tion of   IL-17 compared with their WT counterparts (  Fig. 1 F  ). 
  Figure 2.     Increased IL-17 production by Ets-1 KO Th cells is re-
versible, and is associated with increased expression of Th17 markers. 
(A) Total Th cells from WT and Ets-1 KO mice were infected 2 d after 
activation under Th17 skewing conditions with either empty virus (GFP-rv) 
or virus expressing full-length Ets-1 isoform (Ets-1-rv). The panels are 
gated on GFP-positive cells. The production of IL-17 by the transduced 
(GFP-positive) cells was examined by ICS. Mean fl  uorescence intensity 
(MFI) of the IL-17-positive cells is indicated. Results are representative of 
three independent experiments. (B) After 5 d in culture in the indicated 
conditions, differentiated WT and Ets-1 KO Th cells were restimulated for 
4 h with PMA/ionomycin, and the transcript levels of IL-17F, IL-22, IL-23R, 
and ROR    t were measured by real-time PCR. Data are presented as the 
mean   ±   the SD and are representative of three independent experiments. 
*,  P   <   0.05.   2828 ETS-1 NEGATIVELY REGULATES TH17 DIFFERENTIATION | Moisan et al.
IL-17 than their WT counterparts (  Fig. 3 B  ). Thus, the pre-
dilection for Th17 diff  erentiation of Ets-1 KO Th cells is not 
dependent on APC-derived signals. 
Ets-1 protein in WT Th17 cells probably explains the modest 
effect of the Ets-1-rv transduction on IL-17 production. 
In contrast, transduction with the Ets-1-rv retrovirus led to 
a 50% reduction in the number of IL-17  –  producing cells 
from diff  erentiating Ets-1 KO Th17 cells (  Fig. 2 A  ).   Mean 
fl  uorescence intensity in the Ets-1-rv  –  transduced Ets-1 KO 
cells still expressing IL-17 was also lower than in the GFP-
rv  –  transduced group. Incomplete normalization of IL-17 
production is probably caused by the kinetics of infection. 
Because retroviral transduction requires proliferating cells, 
it is conceivable that at the time of infection on day 2, a pop-
ulation of cells is already committed to IL-17 production. 
These data demonstrate that the increase in IL-17 production 
by Ets-1 KO Th17 cells can be reversed by restoring the ex-
pression of Ets-1, and is thus unlikely to be caused by altered 
thymic development. 
  Although IL-17 is the prototypical cytokine of Th17 
cells, other factors, such as IL-17F, IL-22, ROR    t, and IL-
23R have been found to be associated with cells committed 
to this subset. Defi  ciency of Ets-1 could specifi  cally enhance 
the transcription of the   Il17a   gene. Alternatively, lack of 
Ets-1 could lead to augmented diff  erentiation of Th17 cells. 
In the latter scenario, Ets-1 KO Th17 cells should also over-
express the aforementioned Th17-specifi  c genes. We there-
fore used quantitative real-time PCR to analyze the expression 
of other Th17 marker genes in restimulated WT and Ets-1 
KO Th17 cells (  Fig. 2 B  ). In agreement with published re-
ports, these Th17 marker genes were detected in WT Th17 
cells, but not Th0 cells. Defi  ciency of Ets-1 resulted in a 
striking increase in the levels of all the known Th17 markers. 
This result clearly indicates that Ets-1 inhibits the diff  erentia-
tion of Th17 cells, and not merely the transcription of the 
  Il17a   gene. 
  Ets-1 does not bind to the IL-17 gene or interfere 
with early signaling events during Th17 differentiation 
  We next tried to identify possible mechanisms mediating the 
enhanced Th17 diff  erentiation of Ets-1 KO Th cells. We fi  rst 
determined whether Ets-1 could regulate the expression of 
IL-17 by directly binding to the   Il17a   gene. Several con-
served potential Ets-binding sites in the promoter and fi  rst 
intron of the IL-17 genetic region were tested for Ets-1 bind-
ing by chromatin immunoprecipitation (CHIP). However, 
we could not demonstrate any binding of Ets-1 (  Fig. 3 A  ).   As 
a positive control, substantial binding of Ets-1 to the IFN-     
promoter was detected, a result that is consistent with our 
previously published data (  22  ). In our hands, optimal diff  er-
entiation of Th17 cells requires APCs (irradiated WT spleno-
cytes), IL-6, and TGF    1. Ets-1 KO Th cells may be more 
sensitive than WT cells to signals derived from APCs, thereby 
preferentially diff  erentiating into Th17 cells. To test this 
hypothesis, we cultured WT and Ets-1 KO Th cells under 
Th17 conditions, but in the absence of APC. Although the 
number of IL-17  –  producing cells was lower in both WT and 
Ets-1 KO populations compared with those cultured in the 
presence of APC, Ets-1 KO Th17 cells still produced more 
  Figure 3.     Ets-1 does not bind to the IL-17 promoter or interfere 
with early signaling events during Th17 differentiation. (A) CHIP was 
performed on WT Th17 cells using anti  –  Ets-1 antibody. Binding to con-
served Ets sites in the IL-17 and IFN-     genetic region was analyzed by 
real-time PCR. Relative binding was calculated as described in the Materials 
and methods. (B) Total WT and Ets-1 KO Th cells were plated on anti-
CD3  –  coated plates and given anti-CD28, but in the absence of APC, and 
skewed to the Th17 lineage with IL-6 and TGF    1 for 5 d. The production 
of indicated cytokines by the differentiated Th cells was measured by ICS. 
(C) Freshly isolated total WT and Ets-1 KO Th cells were stimulated with 
TGF    1 and IL-6 for the indicated number of minutes. The levels of phos-
pho-Smad3, total Smad2/3, phospho-STAT3, and total STAT3 were exam-
ined with Western blotting. (D) Naive Th cells were cultured under Th17 
conditions, and RNA was harvested on day 2 or 4 and analyzed for ex-
pression of IL-17 and ROR    t by real-time PCR. Data are representative of 
three independent experiments and are presented as the mean   ±   the SD. 
*,  P   <   0.05.   JEM VOL. 204, November 26, 2007 
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exogenous hIL-2, even added in the beginning of in vitro 
diff  erentiation and whenever Th cells were expanded, may 
not be suffi   cient to equalize the level of IL-2. Such a diff  er-
ence in the level of IL-2 may result in the abnormal Th17 
diff  erentiation of Ets-1 KO cells. To test this hypothesis, 
congenic CD45.1 C57BL/6 and CD45.2 Ets-1 KO cells were 
separately cultured or cocultured under Th17 skewing con-
ditions in the absence of exogenous hIL-2. In this coculture 
  Another possible explanation for increased Th17 diff  er-
entiation is augmented signal transduction from TGF    R and/
or IL-6R. To address this possibility, freshly isolated Th cells 
were stimulated with TGF    1 and IL-6, and the activation of 
proximal signal transduction components were examined by 
Western analysis. No phosphorylated STAT3 was detected 
before the addition of IL-6. Treatment with IL-6 quickly in-
duced the phosphorylation of STAT3 within 15 min, and the 
levels and kinetics of phosphorylation of STAT3 were com-
parable between WT and Ets-1 KO Th cells up to 3  –  6 h after 
IL-6 stimulation (  Fig. 3 C   and not depicted). A low level of 
phosphorylated Smad3 was detected even in the absence of 
exogenous TGF    1 probably caused by preexisting TGF    1 in 
fetal calf serum. The addition of TGF    1 further boosted the 
level of phosphorylated Smad3, which remained relatively 
constant for 60 min before returning to baseline. In most, but 
not all, of the experiments, we detected a subtle increase in the 
level of phosphorylated Smad3 in Ets-1 KO Th cells after the 
addition of exogenous TGF    1 (  Fig. 3 C  ). We therefore con-
clude that early signaling events downstream of TGF    R and 
IL-6R occur normally in Ets-1 KO Th cells. 
  Increased Th17 differentiation in Ets-1 KO Th cells despite 
normal expression of ROR    t 
  ROR    t is essential and suffi   cient for the diff  erentiation of 
Th17 cells (  17  ). The data shown in   Fig. 2 B   indicate a high 
level of ROR    t in the diff  erentiated Ets-1 KO Th17 cells. 
This fi  nding might explain why Ets-1 KO Th17 cells pro-
duce more IL-17 than WT cells. On the other hand, the ele-
vated ROR    t level may simply refl  ect the fact that there are 
more IL-17  –  producing cells in the diff  erentiated Ets-1 KO 
population and that this is not the cause of enhanced Th17 
diff  erentiation. In support of the latter scenario, when naive Th 
cells were examined 2 d into the Th17 diff  erentiation protocol, 
an abnormally high level of IL-17 transcripts was already 
detected in the diff  erentiating Ets-1 KO Th17 cells (  Fig. 3 D  ). 
However, there was no statistically signifi  cant diff  erence in the 
level of ROR    t between WT and Ets-1 KO populations. 
The overproduction of IL-17 by diff  erentiating Ets-1 KO Th17 
cells was even more obvious on the fourth day of the diff  er-
entiation protocol, but the levels of ROR    t were still very 
comparable (  Fig. 3 D  ). These data demonstrate that naive Ets-1 
KO Th cells diff  erentiate more readily than WT into Th17 
cells, and that the enhanced early IL-17 production is not 
associated with an increase in the expression of ROR    t. 
  Defi  ciency of Ets-1 enhances Th17 differentiation 
by an IL-2  –  dependent mechanism 
  IL-2 was recently shown to be a potent inhibitor of Th17 
diff  erentiation (  19  ). Exogenous human IL-2 (hIL-2 at 50 U/ml) 
was added to our Th17 culture conditions without knowing 
the negative eff  ect of IL-2. Our intent had been to equalize 
the level of active IL-2 because Ets-1 KO Th cells, regardless of 
functional subsets, have a substantial defect in IL-2 production. 
The diff  erence in IL-2 production was readily detected even 
at 48 h after the initial stimulation (  22  ). Despite the eff  ort, 
  Figure 4.     Increased Th17 differentiation in Ets-1 KO Th cells is 
dependent on IL-2. (A) Total Th cells from congenic CD45.1 C57BL/6 and 
CD45.2 Ets-1 KO mice were cultured separately or cocultured (Mix) at a 
1:1 ratio under Th17 skewing conditions in the presence (added at 0 h) or 
absence of exogenous IL-2. The cells were stained for the CD45.1 isoform, 
and the production of indicated cytokines was analyzed by ICS after re-
stimulation with PMA/ionomycin. (B) Total Th cells from WT and Ets-1 KO 
mice were cultured under Th17 conditions in the presence of anti  –  mouse 
IL-2 and various concentrations of hIL-2. Cytokine production was as-
sessed by ICS. The numbers represent the percentages of cells stained 
positive for indicated cytokines. (C) Total Th cells from WT and Ets-1 KO 
mice were cultured for 3 d with TGF    1, IL-6, anti  –  mouse IL-2, and hIL-2 
(10 U/ml). Cells were subsequently rested for 2 h in the presence of anti  –
  mouse IL-2 before being stimulated with 50 U/ml hIL-2 for the indicated 
amount of time. Cell lysates were harvested and subjected to Western 
blot analyses using antibody against phosphorylated or total STAT5. The 
blots were scanned and the levels of phosphorylated STAT5 were normal-
ized to the total amount of STAT5. (D) After 5 d in culture in the indicated 
conditions, RNA from differentiated WT and Ets-1 KO Th17 cells was col-
lected, and the transcript level of ROR    t was measured by real-time PCR. 
Data are presented as the mean   ±   the SD and are from two independent 
experiments. *, P   <   0.05.     2830 ETS-1 NEGATIVELY REGULATES TH17 DIFFERENTIATION | Moisan et al.
increased resistance to the negative eff  ects of IL-2. To address 
this question, on day 3 we harvested diff  erentiating WT and 
Ets-1 KO Th17 cells from anti  –  mouse IL-2  –   and hIL-2  –
  treated (10 U/ml) cultures. The cells were washed thoroughly 
and treated with 50 U/ml of fresh hIL-2. The level of phospho-
STAT5 was then examined at diff  erent time points. We found 
that the level and kinetics of STAT5 phosphorylation was very 
comparable between WT and Ets-1 KO Th cells (  Fig. 4 C  ). 
Furthermore, the levels of ROR    t in diff  erentiating WT and 
Ets-1 KO Th17 cells that were cultivated with either 10 or 
50 U/ml of hIL-2 were also comparable (  Fig. 4 D  ). Thus, the 
resistance to IL-2 is not caused by a defect in STAT5 phos-
phorylation or induction of ROR    t. 
  Ets-1 KO mice display increased expression of Th17 markers 
in vivo 
  To determine whether the aberrant Th17 diff  erentiation 
in vitro can also be observed in vivo, we performed expression 
analyses on various organs from WT and Ets-1 KO mice. We 
detected signifi  cant increases in Th17-associated cytokines 
(IL-17, -17F, and -22) in the lungs of Ets-1 KO mice (  Fig. 5, 
A  –  C  ).   In contrast, we did not observe any diff  erence in the 
expression of the Th1 cytokine IFN-     (  Fig. 5 D  ). IL-13 is 
also a potent mediator of airway infl  ammation (  33  ), but we 
found that the transcript level of IL-13 was normal in Ets-1 
KO lung tissue (Fig. S2, available at http://www.jem.org/
cgi/content/full/jem.20070994/DC1). There was also a strong 
system, WT and Ets-1 KO Th cells were allowed to diff  er-
entiate into Th17 cells in the same cytokine milieu, thereby 
avoiding any confounding eff  ects caused by aberrant produc-
tion of endogenous IL-2. We found that the coculture sys-
tem did not alter the production of IL-17 by either Ets-1 KO 
or WT cells (  Fig. 4 A  ).   Thus, the defect in IL-2 production 
cannot fully explain the aberrant Th17 diff  erentiation of 
Ets-1 KO cells. 
  In parallel experiments, exogenous hIL-2 was added to 
the coculture system. Again, the coculture system failed to 
equalize the diff  erentiation of Th17 cells in the presence of 
exogenous hIL-2 (  Fig. 4 A  ). But exogenous hIL-2 strongly 
inhibited the diff  erentiation of WT Th17 cells, a result that is 
consistent with a recent publication (  19  ). Interestingly, the 
negative eff  ect of IL-2 on Ets-1 KO Th17 cells was much less 
dramatic than that on WT cells. This intriguing observation 
raised the possibility that Ets-1 KO  –  diff  erentiating Th17 cells 
were more resistant to IL-2 suppression. To test this hypoth-
esis, we fi  rst determined whether the eff  ect of Ets-1 defi  -
ciency was dependent on IL-2. We set up Th17 diff  erentiation 
in the absence of IL-2/STAT5 signaling. WT and Ets-1 KO 
Th cells were activated in vitro under Th17 conditions, but 
in the absence of exogenous hIL-2. In addition, anti  –  murine 
IL-2 antibody was added in a separate set of samples to fur-
ther neutralize endogenous IL-2. The production of IL-17 
by the diff  erentiated Th17 cells was examined by ICS. Simi-
lar to what was shown in   Fig. 4 A  , Ets-1 KO Th17 cells pro-
duced a much higher level of IL-17 than WT cells when 
diff  erentiated in the absence of exogenous hIL-2 (  Fig. 4 B  ). 
Remarkably, neutralization of endogenous IL-2 markedly 
enhanced IL-17 production by WT Th17 cells to a level 
comparable to that of Ets-1 KO Th17 cells. In contrast, anti  –
  IL-2 had a negligible eff  ect on the production of IL-17 by 
Ets-1 KO Th17 cells. Thus, the Th17-promoting eff  ect of 
Ets-1 defi  ciency is only apparent in the presence of IL-2 sig-
naling, and is therefore dependent on IL-2. 
  Ets-1 KO-differentiating Th17 cells are more resistant 
to IL-2 suppression than WT cells 
  To further examine the response of diff  erentiating Th17 cells 
to IL-2 in a dose-dependent manner, we then added incre-
mental doses of hIL-2 to the culture shown in   Fig. 4 B  . As 
hIL-2 is not recognized by the anti  –  murine IL-2 antibody, 
IL-2 activity in this culture system came solely from exoge-
nous hIL-2. The diff  erentiation of WT Th17 cells started to 
be suppressed by exogenous hIL-2 at a concentration of 
10 U/ml and was almost completely inhibited at 50 U/ml. 
Surprisingly, the diff  erentiation of Ets-1 KO Th17 cells was only 
reduced by 50% at 50 U/ml of hIL-2. Collectively, our data 
clearly demonstrate that Ets-1 KO Th17 cells not only have 
a defect in IL-2 production, but also are more resistant than 
WT cells to IL-2 suppression. 
  IL-2 is known to induce the phosphorylation of STAT5, 
which in turn inhibits the expression of ROR    t in diff  eren-
tiating Th17 cells. Defi  ciency of Ets-1 may aff  ect the level 
and/or kinetics of STAT5 phosphorylation, explaining the 
  Figure 5.     In vivo evidence of increased Th17 differentiation in 
Ets-1 KO mice. Total RNA of indicated tissues from three WT and Ets-1 
KO mice was extracted, and the transcript levels of IL-17 (A), IL-17F 
(B), IL-22 (C), and IFN     (D)  were  quantifi  ed by real-time PCR. (E) Expression 
of various chemokines was analyzed in the lungs of WT and Ets-1 KO mice. 
Data are presented as the mean   ±   the SD. *, P   <   0.05.     JEM VOL. 204, November 26, 2007 
ARTICLE
2831
mice (  Fig. 6 C  ). This observation is consistent with a previous 
study showing that IL-17 is a potent inducer of mucin 
production (  34  ). To confirm that the increased mucus 
production in Ets-1 KO lungs was caused by overproduction 
of IL-17, 2-mo-old Ets-1 KO mice were treated every other 
day for 2 wk with either an anti  –  IL-17 antibody or isotype 
control. Neutralization of IL-17 led to a statistically signifi  cant, 
although modest, reduction in the number of mucus-producing 
cells (  Fig. 6, D and E  ). In addition, the overall staining in 
the remaining PAS-positive cells was less intense in the anti  –
  IL-17  –  treated mice than in control IgG-treated mice. The 
modest eff  ect of anti  –  IL-17 treatment shown in   Fig. 6   is in 
line with that reported in animal models of colitis and arthritis 
(  35, 36  ). These data collectively indicate that the overproduc-
tion of mucus in Ets-1 KO mice can be partially attributed to 
excessive IL-17. 
    DISCUSSION   
  In this study, we report an inhibitory role for the transcription 
factor Ets-1 in Th17 diff  erentiation. Besides STAT molecules 
(  37  ), there are only a handful of transcription factors that have 
been shown to control the diff  erentiation and function of this 
new subset of Th cells. ROR    t is a well-known promoter of 
Th17 cells, whereas Foxp3 and T-bet suppress the diff  eren-
tiation of Th17 cells (  12, 17  ). Diff  erentiated Th17 cells main-
tain a high level of ROR    t (  17  ), but shut off   the expression 
of Foxp3 (  13  ) and T-bet (  38  ). In this regard, Ets-1 is quite 
unique because it is expressed at a substantial level in Th17 
population, despite its function as a negative regulator. 
trend toward higher expression of Th17 markers in Ets-1 KO 
thymus. Interestingly, no signifi  cant diff  erences in the level 
of Th17 markers were observed in the colon of WT and Ets-1 
KO mice, suggesting that the overexpression of Th17 cyto-
kines is restricted to certain organs/tissues. Ectopic expression 
of an IL-17 transgene has been shown to induce the ex-
pression of several chemokines in the lung tissue (  15  ). We 
also detected an abnormally high level of CCL11, but not 
CCL7, CCL20, CCL22, or CXCL1 in the lung of Ets-1 KO 
mice (  Fig. 5 E  ). 
  IL-17  –  dependent overproduction of mucus by Ets-1 KO 
airway epithelial cells 
  Ectopic expression of IL-17 by lung epithelial cells has been 
shown to induce striking airway infl  ammation (  15  ). The ob-
servation that Ets-1 KO mice expressed a high level of IL-17 
in the lungs prompted us to perform thorough histological 
analysis of lungs from WT and Ets-1 KO mice to determine 
whether increased expression of Th17 mediators had any 
pathological consequences. We did not observe any sig-
nifi  cant diff  erences in cellular infi  ltration, fi  brosis, or bron-
choalveolar lavage composition (  Fig. 6 A   and not depicted).   
Interestingly, Ets-1 KO lungs showed a striking increase in 
the number of mucus-producing cells (  Fig. 6 B  ). Approx-
imately 60  –  80% of airway epithelial cells of Ets-1 KO mice 
were stained positive with periodic acid Schiff   (PAS), whereas 
only 0  –  20% of WT epithelial cells produced mucus. This 
marked increase in mucus production was observed as early as 
2 mo after birth, and it was still present in 5-mo-old Ets-1 KO 
  Figure 6.     IL-17  –  dependent mucus overproduction by Ets-1 KO airway epithelial cells. Histological sections of infl  ated lungs from WT and Ets-1 
KO mice were stained for hematoxylin and eosin (A) and PAS (B). Bars, 1 mm. The arrow in B points out PAS-positive epithelial cells. The percentages of 
PAS-positive epithelial cells observed in WT and KO mice (  n   = 3  –  4) at the indicated ages are shown in C. 2-mo-old Ets-1 KO mice were injected intraperi-
toneally with anti  –  IL-17 or control IgG every other day for 2 wk (6 injections in total) before killing. The histological sections of infl  ated lungs were 
stained with PAS (D). The percentages of PAS-positive epithelial cells are shown in F. Data are presented as the mean   ±   the SD.  *,  P   <   0.05.   2832 ETS-1 NEGATIVELY REGULATES TH17 DIFFERENTIATION | Moisan et al.
human T cells (  42  ). STAT5 has been shown to directly bind 
to the promoter of IL-17 (  19  ). Ets-1 may form a protein 
complex with STAT5, and then bind to the IL-17 promoter. 
However, we could not fi  nd any evolutionarily conserved 
STAT5  –  Ets-1 composite sites in the IL-17 locus, nor could 
we demonstrate any direct binding of Ets-1 to the IL-17 gene 
(  Fig. 3 A  ). This may suggest that the target of the STAT5  –
  Ets-1 complex, if indeed present, is not IL-17. Although Ets-1 
KO Th17 cells were resistant to inhibition by IL-2, other 
IL-2  –  induced responses, such as induction of CD25, were 
intact in Ets-1 KO Th cells (unpublished data). Thus, defi  -
ciency of Ets-1 selectively interferes with a novel IL-2  – 
dependent molecular event that is critical for the diff  erentiation 
of Th17 cells. Identifying the target genes of Ets-1 will help us 
understand this novel molecular event. 
  IL-17 is a highly infl  ammatory cytokine, and it is the 
main eff  ector molecule in several organ-specifi  c autoimmune 
diseases, such as experimental autoimmune encephalomyeli-
tis (  43  ), colitis (  36  ), and arthritis (  44  ), in addition to airway 
infl  ammation (  15  ). But why do Ets-1 KO mice not exhibit 
pathological changes in organs other than the lungs? The an-
swer may rest in the observation that the overproduction of 
IL-17 in Ets-1 KO mice is mainly confi  ned to the lungs. This 
observation also strongly suggests that the diff  erentiation of 
Ets-1 KO Th cells is still subject to regulation by local envi-
ronmental factors. Indeed, Ets-1 KO Th cells, despite their 
propensity for Th17 diff  erentiation, still require APC-derived 
signals, IL-6, and TGF    1 to optimally diff  erentiate into IL-17  –
  producing cells. In addition, it was recently shown that en-
gagement of dectin-1 by yeast      glucan  –  activated dendritic 
cells favored the production of IL-23, but not IL-12 (  45  ). 
The dectin-activated dendritic cells then   “  instructed  ”   Th cells 
to become IL-17  –  producing cells. This observation further 
highlights the critical infl  uence of environmental factors in 
determining the fate of diff  erentiating Th cells. Thus, the inter-
plays between Ets-1 KO Th cells and   “  permissive  ”   environ-
mental factors that are present in the lungs, but not the colon, 
lead to lung-restricted overproduction of IL-17. 
  Given the observation that anti  –  IL-17 treatment attenu-
ated mucus production in Ets-1 KO mice, we conclude that 
the overproduction of mucus is at least partally attributed to 
excessive IL-17. It is not unexpected that the eff  ect of anti  –
  IL-17 treatment is only modest for the following reasons. 
First, the dose, timing, and duration of treatment may not be 
optimal. Second, the lungs of Ets-1 KO mice also contain high 
levels of other Th17 cytokines, such as IL-17F and -22, which 
may also directly or indirectly promote mucus production. 
The anti  –  IL-17 antibody used in this study will not block the 
biological function of Th17-cytokines other than IL-17. 
  Our fi  ndings further support a pathogenic role of Th17 
cells in airway inflammation. IL-17  –  deficient mice were 
resistant to airway inflammation in one animal model of 
acute allergic asthma (  46  ). In addition, constitutively forced 
expression of IL-17 by airway epithelial cells induced marked 
lung infl  ammation that was characterized by airway remodeling 
and mucus production (  15  ). But the pathological consequence 
  The diff  erentiation of Th17 cells is regulated by several 
signaling pathways. APC-derived signals, such as signals 
downstream of ICOS/ICOSL (  15  ), critically infl  uence the 
diff  erentiation of Th17 cells. But the preferential Th17 dif-
ferentiation of Ets-1 KO Th cells was still observed in the 
absence of APC. In addition, the strength of early signal trans-
duction events downstream of TGF    R and IL-6R was ap-
parently normal in Ets-1 KO cells. Non-Th17 cytokines, 
such as IFN-     and IL-4, can also inhibit the diff  erentiation of 
Th17 cells. Defi  ciency of Ets-1 attenuates the production of 
IFN-     and IL-4 by Th1 and Th2 cells, respectively, and may 
therefore lead to enhanced Th17 diff  erentiation. However, 
Ets-1 KO and WT Th17 cells produced low, but comparable, 
levels of these two cytokines (  Fig. 1 B   and not depicted). In 
addition, anti  –  IL-4 and   –  IFN-    , when added into Th17 culture 
conditions, were unable to equalize Th17 diff  er  en  tiation of WT 
and Ets-1KO cells (Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20070994/DC1). During the re-
vision of this manuscript, it was reported that IL-21, induced by 
IL-6 via STAT3, facilitated Th17 diff  erentiation in a STAT3-
dependent positive feedback manner (  39  –  41  ). We found that 
the transcript levels of IL-21 in diff  erentiating WT and Ets-1 
KO Th17 cells were comparable (unpublished data). This 
result is consistent with the observation that the level and 
kinetics of IL-6  –  induced STAT3 phosphorylation were normal 
in Ets-1 KO Th cells. It is also unlikely that Ets-1 controls the 
expression of the known Th17 regulators, thereby indirectly 
suppressing the diff  erentiation of Th17 cells. We did not detect 
reduced expression of T-bet in diff  erentiating WT and Ets-1 
KO Th17 cells (unpublished data). Foxp3 was transiently in-
duced during the diff  erentiation of Th17 cells, but the level 
and kinetics of induction of Foxp3 were normal in Ets-1 KO 
Th cells (Fig. S4). 
  Our data instead indicate that the eff  ect of Ets-1 defi  -
ciency on Th17 diff  erentiation is only apparent in the pres-
ence of IL-2. IL-2 is known to inhibit Th17 diff  erentiation 
by suppressing the expression of ROR    t (  19  ). Ets-1 KO Th 
cells have a profound defect in the production of IL-2. Such 
a defect surely facilitates Th17 diff  erentiation because elimi-
nating IL-2 from the culture markedly enhanced the diff  eren-
tiation of WT Th17 cells. But our data further demonstrate 
that diff  erentiating Ets-1 KO Th cells are also more resistant 
to the negative eff  ect of IL-2. This resistance was clearly 
revealed when the level of bioactive IL-2 in cytokine milieu 
was normalized either by the coculture system or by the com-
bination of anti  –  murine IL-2 and hIL-2. More importantly, 
we found that the resistance was not caused by a defect in the 
phosphorylation of STAT5 or in the induction of ROR    t. 
This observation strongly suggests that IL-2 can also inhibit 
the diff  erentiation of Th17 cells by acting on a molecular 
event that takes place after the induction of ROR    t. To the best 
of our knowledge, this is the fi  rst evidence showing that IL-2 
can suppress the diff  erentiation of Th17 cells by a mechanism 
diff  erent from suppressing the induction of ROR    t. 
  It is intriguing to know that an early study has demon-
strated physical interactions between Ets-1 and STAT5 in JEM VOL. 204, November 26, 2007 
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six generations. All experiments were performed using 6  –  8-wk-old male or 
female littermate pairs. Heterozygous mice were used as WT controls. Con-
genic CD45.1 C57BL/6 mice were purchased from Taconic. The animals 
were housed under specifi  c pathogen-free conditions, and experiments were 
performed in accordance with the institutional guidelines for animal care at 
the Dana-Farber Cancer Institute under approved protocols. 
  Antibodies and cytokines.     Anti-CD3 (2C11) and -IFN     (XMJ 1.2) were 
purchased from BD Biosciences. Recombinant hIL-2 and anti  –  IL-4 (11B11) 
were provided by the National Cancer Institute. IL-12 and -4 were obtained 
from Peprotech. TGF    1, IL-6, and anti  –  mouse IL-2 were purchased from 
R  &  D Systems. The following antibodies for surface and intracellular cyto-
kine staining were purchased from BD Biosciences: CD4 (L3T4), CD25 
(PC61), CD44 (IM7), CD62L (MEL-14), IFN     (XMJ 1.2), IL-2 (JES6-
5H4), IL-4 (11B11), IL-10 (JES5-16E3), and IL-17 (TC11-18H10). For 
in vivo IL-17 neutralization, anti  –  IL-17 (50104) and control rat IgG2a were 
purchased from R  &  D Systems. 
  Cell purifi   cation and in vitro diff  erentiation.     Spleen and peripheral 
lymph nodes were harvested from WT and Ets-1 KO mice. Total CD4  +   
cells were purifi  ed using magnetic cell separation according to the manufac-
turer  ’  s protocol (Miltenyi Biotech). To obtain naive Th cells, CD4  +   cells 
were stained for CD4, CD25, and CD62L and sorted on a High-Speed 
MoFlo sorter (DakoCytomation). The CD4  +  CD25    −   CD62L  hi   population was 
used for in vitro Th cell diff  erentiation. Total or sorted CD4  +   naive cells 
were cultured in the presence of WT irradiated splenocytes (1:3 ratio) and 
2     g/ml soluble anti-CD3 in the presence of cytokines to obtain either Th0 
(no additional cytokines or antibodies), Th1 (3 ng/ml IL-12 and 10     g/ml 
anti-IL-4), Th2 (10 ng/ml IL-4 and 10     g/ml anti-IFN-    ), or Th17 (3 ng/ml 
TGF    1 and 20 ng/ml IL-6) cells. 50 U/ml IL-2 was added to the cul-
tures after 24 h. Analysis of cytokine production was performed 5 d later. 
Retroviral transduction was performed 2 d after activation. The protocol for 
retroviral transduction and the GFP-rv and Ets-1-rv construct have been 
previously described (  22  ). 
  Analysis of cytokine production.     Intracellular cytokine staining was per-
formed as previously described (  50  ). After staining, the samples were run on 
a FACSCanto fl   ow cytometer (BD Biosciences) and analyzed using the 
FlowJo software package. IL-17 Duoset ELISA kit was purchased from 
R  &  D Systems and used according to the manufacturer  ’  s protocol. 
  Histology.     Immediately after the killing of the mouse, the lungs were 
removed, infl  ated with 4% paraformaldehyde, dehydrated, mounted in paraf-
fi  n, and sectioned. Deparaffi   nized and hydrated sections were stained with 
of excessive IL-17 derived from bona fi  de IL-17  –  producing 
cells, namely Th17 cells, in response to physio  logical stim-
uli remains unclear. Our data indicate that chronic exposure 
to Th17 cell  –  derived cytokines can, indeed, lead to mucus 
overproduction. However, we did not detect any abnormal 
cellular infi  ltration or increased fi  brosis, which is a feature of 
airway remodeling, in the lungs of 5-mo-old Ets-1 KO mice. 
The development of cellular infi  ltration and fi  brosis may re-
quire a longer exposure to a higher level of Th17-derived 
cytokines than that was detected in the relatively young Ets-1 
KO lungs. It is also possible that lung tissue may respond dif-
ferently to Th17-derived cytokines compared with ectopi-
cally expressed IL-17. The diff  erences in the level and source 
of IL-17 between Ets-1 KO mice and the IL-17 transgenic 
mice may also explain why we only observed aberrant ex-
pression of CCL11, but not other chemokines in the lung of 
Ets-1 KO mice. 
  Elevated levels of IL-17 have been reproducibly detected 
in bronchial lavage obtained from patients with allergic 
asthma (  2, 47  ), and the contribution of Th17 cells to the 
pathogenesis of this disease has begun to be elucidated. Our 
data raise the possibility that loss of Ets-1 function may indi-
rectly lead to exacerbation of asthma in a subset of patients by 
boosting the production of IL-17 by pulmonary Th cells. The 
chromosomal locus of the   ets1   gene is not known to be asso-
ciated with susceptibility to allergic asthma. But it has been 
demonstrated in vitro that the transcriptional activity of Ets-1 
is subject to regulation by posttranslational modifi  cations, in-
cluding phosphorylation and sumoylation, in response to various 
signals (  25, 27  –  29, 48  ). It is foreseeable that the activity of Ets-1 
can be manipulated by altering the posttranslational modi-
fi  cations with pharmacological and/or biological reagents. Such 
reagents carry the potential of becoming eff  ective treatments 
for allergic asthma. 
    MATERIALS AND METHODS   
  Mice.     The Ets-1 KO mice have been previously described (  49  ). Mice used 
in these experiments have been backcrossed to the C57BL/6 background for 
    Table I.        Sequences used in this study 
Gene Sense (5  ’    –  3  ’  ) Antisense (5  ’    –  3  ’  ) Primer bank ID
IL-13 GCAACATCACACAAGACCAGA GTCAGGGAATCCAGGGCTAC 6680403a2
IL-17A actttcagggtcgagaaga ttctgaatctgcctctgaat
IL-17F TGCTACTGTTGATGTTGGGAC AATGCCCTGGTTTTGGTTGAA 22003916a1
IL-22 GTGAGAAGCTAACGTCCATC GTCTACCTCTGGTCTCATGG
IL-23R TTCAGATGGGCATGAATGTTTCT CCAAATCCGAGCTGTTGTTCTAT 21362353a1
IFN   tgaacgctacacactgcatct cgactccttttccgcttcctg
ROR    t AGCTTTGTGCAGATCTAAGG TGTCCTCCTCAGTAGGGTAG
CCL7 GCTGCTTTCAGCATCCAAGTG CCAGGGACACCGACTACTG 7305463a1
CCL11 GAATCACCAACAACAGATGCAC ATCCTGGACCCACTTCTTCTT 6755418a1
CCL20 GCCTCTCGTACATACAGACGC CCAGTTCTGCTTTGGATCAGC 8394248a1
CCL22 AGGTCCCTATGGTGCCAATGT CGGCAGGATTTTGAGGTCCA 6677879a1
CXCL1 CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC 6680109a1
    -actin AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT2834 ETS-1 NEGATIVELY REGULATES TH17 DIFFERENTIATION | Moisan et al.
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hematoxylin and eosin and PAS stains following standard procedure. For quanti-
tation, 300 airway epithelial cells in the lungs were counted in a blinded fashion, 
and the number of PAS-positive cells was quantifi  ed. 
  Western blotting.     2   ×   10  6   CD4  +   cells were lysed in SDS-PAGE sample 
buff  er containing 2.5% 2-mercaptoethanol. The lysates were subsequently 
sheared using a 26-gauge needle. Samples were loaded onto 8% polyacryl-
amide gels and transferred onto PVDF membrane (Polyscreen; Perkin Elmer). 
The membrane was subsequently blocked in 5% milk and probed with 
antibodies according to the manufacturer  ’  s protocol. The Ets-1 (C-20) and 
HSP90 antibodies were purchased from Santa Cruz Biotechnology. Anti-
phospho T38 was purchased from Biosource. Phospho-Smad3, total Smad3, 
phospho-STAT3, total STAT3, phospho-STAT5, and total STAT5 anti-
bodies were obtained from Cell Signaling Technology. 
  RNA analysis.     Total RNA was purifi  ed using a Trizol Plus kit (Invitrogen). 
First-strand cDNA synthesis was performed on 1     g of total RNA using the 
QuantiTect Reverse Transcription kit (QIAGEN). Gene expression levels were 
determined by real-time PCR analysis performed using the Brilliant SYBR 
Green QPCR kit according to the manufacturer  ’  s protocol (Stratagene) on a 
MX-3000P apparatus (Stratagene) using the following cycling conditions: dena-
turation at 95  °  C for 30 s, annealing at 56  °  C for 60 s, and extension at 72  °  C for 
30 s. Primer sets were designed using the Primer3 web utility or using the Primer 
Bank database (  51  ). Sequences used in this study are presented in   Table I   and 
were confi  rmed to generate only one product with a minimum of 90% effi   ciency.   
Levels of cytokine mRNA were adjusted for diff  erences in     -actin expression 
and normalized to the levels found in the Ets-1 WT group, where indicated. 
  CHIP.     CHIP was performed as previously described (  22  ). Precipitated DNA 
fragments were amplifi  ed by quantitative PCR. The antibodies used for 
immunoprecipitation were anti-Ets1 (C-20) and rabbit control IgG (both from 
Santa Cruz Biotechnology). Identifi  cation of conserved Ets-binding site was 
done using the rVista 2.0 web utility (  52  ). IL-17 Ets sites were located at site 1 
(5 kb upstream of the transcriptional start site), site 2 (within the fi  rst intron), 
and site 3 (1 kb upstream of the transcriptional start site). All sites were con-
served between mouse and rat genomes. Additionally, site 1 was conserved in 
human and dog genomes. Specifi  c binding was calculated as follows: specifi  c 
binding = 2^   −   (Ct  Ets1  -Ct  input  )/2^   −   (Ct  rbIg     −   Ct  input  ). The following primer 
pairs were used: IL17-site1, 5    -CGTGTGGTTTGGTTTACTTA-3     and 
5    -GCTGACTTCATCTGATACCC-3    ; IL17-site2, 5    -TATGCTCT-
GCACTCGTATTC-3     and 5    -GTACACCAGCTATCCTCCAG-3    ; 
IL17-site3, 5    -GGGATGTTAATTCAAACTGC-3     and 5    -CTCACA-
CACACCTCTGATTG-3    ; and IFN-     promoter, 5    -CTTTCAGAGA-
ATCCCACAAG-3     and 5    -TTAAGATGGTGACAGATAGGTG-3    . 
  Statistical analysis.     A Mann-Whitney nonparametric test was performed 
to calculate statistical signifi  cance for all experiments, except for the in vivo 
IL-17 neutralization, where an unpaired   t   test using Welch correction was 
performed (Prism 4; GraphPad Softwares). Diff  erences among treatments are 
considered signifi  cant if P   ≤   0.05. 
  Online supplemental material.     Fig. S1 shows ICS staining of various Th 
subsets derived from WT cells after restimulation with PMA/ionomycin. 
Fig. S2 shows expression of IL-13 in the lungs of WT and Ets-1 KO mice. 
Fig. S3 shows WT and Ets-1 KO Th17 diff  erentiation in the presence of neu-
tralizing antibodies to IL-4 and IFN    . Fig. S4 represents FoxP3 expression in 
diff  erentiating WT and Ets-1 KO Th17 cells. The online version of this article 
is available at http://www.jem.org/cgi/content/full/jem.20070994/DC1. 
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